ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
主要な著者: | , , , , , , , , , , , , , , , |
---|---|
フォーマット: | Conference item |
出版事項: |
Oxford University Press
2017
|